MGCPQQ(r) is a bioactive form of PQQ. It is produced naturally by fermentation. It is a registered ingredient on the Novel Food Ingredients List of the European Union.
Several studies have shown that dietary PQQ exposure increases various indices of oxidative metabolism. It also improves mitochondrial-related amino acid metabolism and amounts of mtDNA. It is also associated with decreased risk of metabole disorders. Among other effects, it promotes anti-inflammatory potential.
Among other functions, PQQ affects a variety of genes important for cellular signaling and nutrient transport. It may act through cell surface receptors. It may also influence phosphorylation of key components. It is believed that PQQ may act through growth factor receptors.
The presence of PQQ in cells may contribute to the apoptose process, which is involved in cell death. Moreover, it is linked to neuroinflammmatie. It is thought that PQQ might reduce the risk of neuroinflammmatie by stimulating autofagie.
It is known that the presence of PQQ in mice is related to an attenuated inflammatory response involving CRP and IL-6. IL-6 is responsible for regulating B cell differentiation and plasmacytogenesis. The reduction of inflammatory responses associated with IL-6 is a positive validation of the anti-inflammatory properties of PQQ. It is also believed that IL-6 helps regulate acute phase reactions.
MGCPQQ(r) is considered to be the world’s first bioactive PQQ developed for food application. It is only available in Europe from nutraceutical companies. It is a very potent ingredient.
MGC PQQ(r) is a patented compound that has been approved by the European Union. It is a bioactive form of PQQ and is used in combination with CoQ10. It is registered on the Novel Food Ingredients List of the EU.